Abstract:Currently, the curative effects of polypeptide drugs are often restricted due to the short in vivo duration of action. In this study, we fused a series of heptapeptide tags with different length fatty chains to the N-terminus of mutated glucagon-like peptide-1 (GLP-1) using an intermediate sequence comprising a flexible linker (GGGGS)2 and thrombin (TBN)-cleavable site (FNPR), to develop promising prolonged GLP-1 receptor (GLP-1R) agonists. As a result, twenty-one fusion peptides, termed PES01-PES21, were designed and prepared. Surface plasmon resonance (SPR) measurements and plasma stability tests showed that PES14 exert better albumin binding affinity and in vitro plasma stability compared with the other ones. Preclinical assay in db/db mice proved that PES14 exert the hypoglycemic efficacies in a dose-dependent model within the range of 10-90 nmol kg-1. Furtherly, an enhanced glucose-lowering effect and significantly prolonged hypoglycemic duration of PES14 were exhibited in multiple oral glucose tolerance tests (OGTTs) and hypoglycemic duration test, compared with Liraglutide and Semaglutide, respectively. Moreover, the in vivo t 1/2 of intact PES14 and released GLP-1 were approximately 95.1 h and 110.5 h in rhesus monkeys after a single subcutaneous injection of 90 nmol kg-1, respectively. Furthermore, long-term treatment with PES14 in db/db mice for 8 weeks obtained beneficial efficacies on body weight gain, food intake, fat% and hemoglobin A1c (HbA1c) reduction compared with the control and superior to those of Semaglutide treatment. Meanwhile, chronic treatment of PES14 also exhibited proper insulin immunoreactivity and effectively enhanced the improvement on hepatocyte damage. All these results suggested that PES14 has the potential to be developed as a once-weekly anti-diabetic drug.

The Study on PEGylation and Biological Activity of Insulinotropic Analogues

C-terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/db Mice.

A Site-Specific PEGylated Analog of Exendin-4 with Improved Pharmacokinetics and Pharmacodynamics in Vivo

Development of a C‐Terminal Site‐Specific PEGylated Analog of GLP‐1 with Improved Anti‐Diabetic Effects in Diabetic Mice

Microwave-assisted Solid Phase Synthesis, PEGylation, and Biological Activity Studies of Glucagon-Like Peptide-1(7–36) Amide

Mpegylation of Insulin and Characterization of Its Activity

Preparation and Characterization of Monomethoxypoly(ethylene Glycol)-Insulin Conjugates.

Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

Supramolecular Approaches for Insulin Stabilization Without Prolonged Duration of Action

Di-PEGylated Insulin: A Long-Acting Insulin Conjugate with Superior Safety in Reducing Hypoglycemic Events

Modified Condition Optimization of the Pegylation of Glucagon-like Peptide-

Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.

Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.

How PEGylation Enhances the Stability and Potency of Insulin: a Molecular Dynamics Simulation.

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1

Exenatide-loaded Glucose-Responsive Microspheres for Intelligent Diabetic Therapy

Synthesis and purification of mono-PEGylated insulin.

Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-like Peptide-1 Conjugates.

Hypoglycemic Effect of Intravenous Polyethylene Glycol-Coated Liposomal Insulin on Normal Rats